Literature DB >> 7747813

Analysis of the chromogranin A post-translational cleavage product pancreastatin and the prohormone convertases PC2 and PC3 in normal and neoplastic human pituitaries.

R V Lloyd1, L Jin, X Qian, B W Scheithauer, W F Young, D H Davis.   

Abstract

Several members of the chromogranin/secretogranin (Cg/Sg) family are post-translationally processed in neuroendocrine cells and tumors to smaller peptides, some of which are biologically active. For example, CgA is processed to pancreastatin, parastatin, and other peptides. We analyzed the distribution of pancreastatin and CgA proteins in normal and neoplastic pituitaries as well as the prohormone convertases PC2 and PC3/1 (PC3), the putative processing enzymes for the Cg/Sg family, in 35 pituitary adenomas and 4 non-neoplastic pituitaries by immunohistochemistry and immunoblotting with highly specific antisera. CgA and CgB mRNAs were also examined. Pancreastatin was present in all subtypes of pituitary tumors, although prolactin-secreting adenomas expressed this peptide less frequently than did other tumor types. CgA protein and CgA mRNA expression were also restricted in prolactin adenomas and in normal prolactin cells, as shown by combined in situ hybridization and immunostaining. The prohormone convertases PC2 and PC3 were present in pituitary tumors and in non-neoplastic pituitaries. Immunoblot analysis and immunostaining showed a principal approximately 69-kd PC3 band and a approximately 68-kd PC2 band. Adrenocorticotrophic hormone-secreting adenomas expressed mainly PC3 as determined by immunoblotting and immunohistochemistry, whereas all other adenoma groups expressed predominantly PC2. These results indicate that the enzymes capable of processing CgA and other members of the Cg/Sg family to peptides with biological activity such as pancreastatin are widely expressed in human pituitary adenomas and in non-neoplastic pituitaries, with adrenocorticotrophic hormone tumors expressing predominantly PC3 and other adenomas expressing mainly PC2. The infrequent expression of CgA protein and pancreastatin peptides in normal and neoplastic prolactin cells suggests a unique role of CgA in these tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747813      PMCID: PMC1869270     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Proteolytic processing of chromogranin A in purified insulin granules. Formation of a 20 kDa N-terminal fragment (betagranin) by the concerted action of a Ca2+-dependent endopeptidase and carboxypeptidase H (EC 3.4.17.10).

Authors:  J C Hutton; H W Davidson; M Peshavaria
Journal:  Biochem J       Date:  1987-06-01       Impact factor: 3.857

2.  The primary structure of human chromogranin A and pancreastatin.

Authors:  D S Konecki; U M Benedum; H H Gerdes; W B Huttner
Journal:  J Biol Chem       Date:  1987-12-15       Impact factor: 5.157

3.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

4.  A nomenclature proposal for the chromogranin/secretogranin proteins.

Authors:  L E Eiden; W B Huttner; J Mallet; D T O'Connor; H Winkler; A Zanini
Journal:  Neuroscience       Date:  1987-06       Impact factor: 3.590

5.  Chromogranin from normal human adrenal glands: purification by monoclonal antibody affinity chromatography and partial N-terminal amino acid sequence.

Authors:  B S Wilson; S H Phan; R V Lloyd
Journal:  Regul Pept       Date:  1986-02

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion.

Authors:  K Tatemoto; S Efendić; V Mutt; G Makk; G J Feistner; J D Barchas
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

8.  Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues.

Authors:  W E Schmidt; E G Siegel; R Lamberts; B Gallwitz; W Creutzfeldt
Journal:  Endocrinology       Date:  1988-09       Impact factor: 4.736

9.  Expression patterns of messenger ribonucleic acids encoding prohormone convertases (PC2 and PC3) in human pituitary adenomas.

Authors:  K Hashimoto; M Koga; H Kouhara; N Arita; T Hayakawa; T Kishimoto; B Sato
Journal:  Clin Endocrinol (Oxf)       Date:  1994-08       Impact factor: 3.478

10.  Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA.

Authors:  L J Helman; T G Ahn; M A Levine; A Allison; P S Cohen; M J Cooper; D V Cohn; M A Israel
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

View more
  20 in total

Review 1.  Neuroendocrine secretory protein 7B2: structure, expression and functions.

Authors:  M Mbikay; N G Seidah; M Chrétien
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

2.  The changing faces of corticotroph cell adenomas: the role of prohormone convertase 1/3.

Authors:  Alberto Righi; Marco Faustini-Fustini; Luca Morandi; Valentina Monti; Sofia Asioli; Diego Mazzatenta; Antonella Bacci; Maria Pia Foschini
Journal:  Endocrine       Date:  2016-08-04       Impact factor: 3.633

3.  Immunocytochemical localization of prohormone convertase 1/3 and 2 in gastrointestinal carcinoids.

Authors:  T Tomita
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

4.  Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.

Authors:  A P Heaney; W J Curry; K M Pogue; V L Armstrong; M Mirakhur; B Sheridan; C F Johnston; K D Buchanan; A B Atkinson
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

5.  Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.

Authors:  S Ohta; S Nishizawa; Y Oki; T Yokoyama; H Namba
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

6.  Immunocytochemical Localization of Prohormone Convertase 1/3 and 2 in Thyroid C-Cells and Medullary Thyroid Carcinomas.

Authors:  Tatsuo Tomita
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

7.  Insulin and Glucagon mRNA Expression and Prohormone Convertase Immunoreactivity in Normal and Neoplastic Pancreatic Endocrine Tissue.

Authors:  Mark Rodacker; Long Jin; Shuga Zhang; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

8.  Overview of Neuroendocrine Cells and Tumors.

Authors:  Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

9.  Vascular Endothelial Growth Factor (VEGF) Expression in Human Pituitary Adenomas and Carcinomas.

Authors:  Ricardo V. Lloyd; Bernd W. Scheithauer; Takao Kuroki; Sergio Vidal; Kalman Kovacs; Lucia Stefaneanu
Journal:  Endocr Pathol       Date:  1999       Impact factor: 3.943

Review 10.  Gene expression in prolactinomas: a systematic review.

Authors:  Justin Seltzer; Thomas C Scotton; Keiko Kang; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.